Daniel V. Santi
Fondatore presso Prolynx LLC
Posizioni attive di Daniel V. Santi
Società | Posizione | Inizio | Fine |
---|---|---|---|
Prolynx LLC
Prolynx LLC Miscellaneous Commercial ServicesCommercial Services Prolynx LLC engages in the development of proprietary drug delivery system for half-life extension of proteins, peptides, and small molecules. Its pipeline includes PLX038, PEG-PARP, IL-15, IL-2, PTH 1-34, GLP-1RA, and QMo IVT. The company was founded by Daniel V. Santi and Gary W. Ashley in 2010 and is headquartered in San Francisco, CA. | Direttore/Membro del Consiglio | 01/01/2010 | - |
Fondatore | 01/01/2010 | - | |
Presidente | 01/01/2010 | - |
Storia della carriera di Daniel V. Santi
Precedenti posizioni note di Daniel V. Santi
Società | Posizione | Inizio | Fine |
---|---|---|---|
Kosan Biosciences, Inc.
Kosan Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Kosan Biosciences, Inc. develops drugs for cancer therapeutics. The company was founded in 1995 and is headquartered in New York, NY. | Presidente | - | 14/02/2006 |
Fondatore | - | 14/02/2006 | |
Presidente | - | 14/02/2006 | |
The University of California, San Francisco | Corporate Officer/Principal | 01/01/1974 | 01/01/2001 |
Formazione di Daniel V. Santi
The State University of New York | Doctorate Degree |
The University of California, San Francisco | Doctorate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 5 |
Posizioni
Founder | 2 |
President | 2 |
Doctorate Degree | 2 |
Settori
Consumer Services | 3 |
Health Technology | 2 |
Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 2 |
---|---|
Kosan Biosciences, Inc.
Kosan Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Kosan Biosciences, Inc. develops drugs for cancer therapeutics. The company was founded in 1995 and is headquartered in New York, NY. | Health Technology |
Prolynx LLC
Prolynx LLC Miscellaneous Commercial ServicesCommercial Services Prolynx LLC engages in the development of proprietary drug delivery system for half-life extension of proteins, peptides, and small molecules. Its pipeline includes PLX038, PEG-PARP, IL-15, IL-2, PTH 1-34, GLP-1RA, and QMo IVT. The company was founded by Daniel V. Santi and Gary W. Ashley in 2010 and is headquartered in San Francisco, CA. | Commercial Services |
- Borsa valori
- Insiders
- Daniel V. Santi
- Esperienza